Clinical Trial Detail

NCT ID NCT02383927
Title Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Kura Oncology, Inc.
Indications

head and neck squamous cell carcinoma

squamous cell carcinoma

thyroid gland cancer

Therapies

Tipifarnib

Age Groups: adult senior

Additional content available in CKB BOOST